Hemoglobinopathies

In a recent announcement, bluebird bio, Inc, said a diagnosis of MDS in patient with sickle cell disease treated with their investigational gene therapy LentiGlobin has been revised to transfusion-dependent anemia. The company had previously stated in March that LentiGlobin was unlikely to have caused AML in a second patient who participated in the same study.